Halozyme Therapeutics, Inc. (HALO)

Healthcare

$110.42

+0.53%

nightly snapshot · 10/11/2026

ALPHASCORE™ · B · Watch

ALPHASCORE

61

/ 100

B

WATCH

▲ 0 · 30D

KEY FUNDAMENTALS

P/E32.3

ROE649.2%

NET MARGIN22.7%

GROSS MARGIN83.6%

MKT CAP$12.53B

loading full analysis…

DAILY BRIEF

Halozyme Therapeutics, Inc. holds an AlphaScore of 61/100, yielding a watch signal in the healthcare sector as of October 11, 2026. Relevant fundamentals include a high gross margin of 83.62 and a forward P/E of 10.39. A primary strength is its exceptional return on equity (ROE) of 649.18, reflecting elite profitability efficiency. A major risk is its extremely high debt-to-equity ratio of 43.89, highlighting substantial financial leverage. Evidence is limited to the provided dataset.

Written 11/10/2026, 00:43:34 UTC · Snapshot 11/10/2026